Insulet (PODD) Misses Q3 EPS by 7c

Insulet (NASDAQ: PODD) reported Q3 EPS of ($0.33), $0.07 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $87.3 million versus the consensus estimate of $83.56 million.

Guidance:

For the year ending December 31, 2015, the Company is raising the low end of its revenue expectations to a range of $310 to $320 million, from $305 to $320 million. This represents year-over-year revenue growth of 9% at the mid-point of the range.

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); Insulet Corporation (NASDAQ: PODD); Intuit Inc. (INTU); and Power Solutions International, Inc. (NASDAQ: PSIX): Graba
• General Aerospace (GE) Tops Q2 EPS by 16c, Beats on Revenue; Offers FY26 EPS Guidance
• UnitedHealth Group (UNH) Tops Q2 EPS by $1.53, Beats on Revenue; Offers FY26 EPS Guidance